HLA Binding Peptide-Based Designing of Non-Spike Universal Nanovaccine Against SARS-CoV-2: A Computational Approach
Biophysica · 25.06.2026 · 6 (4) · 55
DOI: 10.3390/biophysica6040055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biophysica, online erschienen am 25.06.2026. Verfasst von Puja Jaishwal und 1 weiteren Autor:innen. Die Arbeit nennt 246 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The continuous evolution of the SARS-CoV-2 virus, marked by the emergence of new variants, poses a significant threat to the efficacy of existing vaccines. However, a promising approach to addressing vaccine failure caused by viral mutations (particularly in the spike protein) is the development of a variant-proof (conserved), non-spike, multiepitope universal nanostructure vaccine with multifunctionality, biocompatibility, self-adjuvanticity, and structural similarity to pathogens in terms of size and shape. This study aimed to design a self-assembled nanostructure vaccine (SANV) featuring pentameric and trimeric coiled-coil peptide motifs, as well as other functional motifs, including epitopes, TAT, PADRE, and adjuvant. The cytotoxic T lymphocyte (CTL), helper T lymphocyte (HTL), and B lymphocyte (BL) epitopes of SANV were screened from the IEDB with more than 50% individual predicted population coverage (PPC) and fused using linkers to enable self-assembly. The multimerization of the 24 SANV monomers was modeled using the GalaxyHomomer and AlphaFold web servers. Subsequently, the leading SANV constructs with (SANVa9) and without (SANVb6) adjuvant were analyzed for their physicochemical profiles and assessed for antigenicity, allergenicity, solubility, and antioxidant potential. Furthermore, the molecular interactions, specificity, and stability of SANVa9 and SANVb6 with the broadly neutralizing sarbecovirus antibody 5817 and toll-like receptors (TLR2, TLR3, and TLR7) were analyzed using molecular docking and simulation over a 100-nanosecond time scale. Finally, the comparative immune simulation profiles of SANVa9 and SANVb6 with controls indicated stronger, broad-spectrum immune responses that could be translated into in vitro and in vivo studies and warrant further evaluation before clinical use.
Zitieren
APA
Jaishwal, P., & Singh, S. P. (2026). HLA Binding Peptide-Based Designing of Non-Spike Universal Nanovaccine Against SARS-CoV-2: A Computational Approach. Biophysica, 6(4), 55. https://doi.org/10.3390/biophysica6040055
Vancouver
Jaishwal P, Singh SP. HLA Binding Peptide-Based Designing of Non-Spike Universal Nanovaccine Against SARS-CoV-2: A Computational Approach. Biophysica. 2026;6(4):55. doi:10.3390/biophysica6040055
BibTeX
@article{Jaishwal2026,
author = {Jaishwal, Puja and Singh, Satarudra Prakash},
title = {HLA Binding Peptide-Based Designing of Non-Spike Universal Nanovaccine Against SARS-CoV-2: A Computational Approach},
journal = {Biophysica},
year = {2026},
volume = {6},
number = {4},
pages = {55},
doi = {10.3390/biophysica6040055}
}
EUVIMED